BeyondSpring Inc. (BYSI) is a global, clinical-stage biopharmaceutical company that is dedicated to the development and commercialization of innovative immuno-oncology cancer therapies. The company was founded in 2010, and since then, it has focused on harnessing the body's immune system to combat cancer. BYSI's headquarters are in New York City, USA, with additional operations in China.
The flagship product of BeyondSpring is Plinabulin, a marine-derived small-molecule immune modulator and microtubule destabilizer. It's currently being tested in clinical trials for the treatment of non-small cell lung cancer and for the prevention of chemotherapy-induced neutropenia, an abnormally low count of neutrophils, a type of white blood cell that aids in fighting off infections in the body.
A unique feature of Plinabulin is its dual-action mechanism which, when combined with different types of cancer therapies, can increase their efficacy and reduce their side effects. This makes it an attractive choice for combination therapies in cancer treatment.
Beyond its development of Plinabulin, BeyondSpring is also building a robust pipeline of preclinical candidates to complement and expand its cancer-fighting capabilities. This pipeline includes innovative small molecules and monoclonal antibodies focused on targets like the toll-like receptor 4 (TLR4) and the inducible T cell co-stimulator (ICOS), among others.
BeyondSpring has always noted the immense potential in the field of immunotherapy, considering it to be the future of cancer treatment. The company is backed by an experienced management team, with a proven track record of cancer drug development and successful commercialization, who are committed to bringing benefit to patients and creating values for shareholders and the medical community.
BeyondSpring Inc. is listed on NASDAQ under the ticker symbol BYSI. Its engagement in quality research and development, backed by a proactive approach towards addressing the pressing needs in the fight against cancer, certainly validates BeyondSpring as a genuine innovator in the global immuno-oncology space. It continues to strive to revolutionize cancer treatment, prioritizing the best possible outcomes for patients worldwide.